Narrative review suggests adjuvant pembrolizumab benefits selected high-risk renal cell carcinoma patients.
Old cancer drugs failed, but one new drug saves high-risk kidney patients today.
This narrative review evaluates adjuvant therapies for renal cell carcinoma, including cytokine-based immunotherapy, VEGF-targeted agents, a…
Doctors finally have a powerful new tool to stop kidney cancer from coming back after surgery, but it only works for specific patients.
Open-sourcing data and annotations for renal cell carcinoma yielded 142 annotated CT scans from 101 patients.
Open-source CT scans aim to boost kidney cancer AI research
This cohort study involved 101 patients with renal cell carcinoma (RCC) and analyzed 142 annotated CT scans. After quality control, the data…
Researchers release 142 annotated CT scans from 101 kidney cancer patients to accelerate AI development.
Targeted therapy versus non-targeted therapy in renal cell carcinoma patients.
Real-world study in Taiwan shows targeted therapy offers similar life expectancy for advanced kidney cancer compared to non-targeted therapy.
This real-world cohort study analyzed 14,131 renal cell carcinoma cases in Taiwan from 1998 to 2016. Patients receiving targeted therapy sho…
In Taiwan, targeted therapy for advanced kidney cancer offers similar life expectancy to non-targeted therapy, with both groups living aroun…
Predictors of pathological upstaging in clinical stage T1 renal cell carcinoma include male gender, age, and irregular margins.
Could your kidney tumor look smaller than it really is inside?
This meta-analysis and systematic review evaluated 24,957 patients with clinical stage T1 renal cell carcinoma to identify predictors of pat…
A kidney tumor that looks small on a scan might actually be more advanced than doctors think, raising the risk of it returning after surgery…
CD8 PET imaging shows modest correlation with biopsy CD8 counts in solid tumor patients on immunotherapy
New imaging method shows modest link to immune cell counts in solid tumors
A Phase II prospective multicenter study of 49 patients with solid tumors receiving immune checkpoint blockade found a modest correlation (c…
A new PET scan shows a modest link to immune cell counts inside solid tumors, with stronger results in kidney cancer patients.
PI3K-AKT-mTOR pathway activation linked to renal cell carcinoma progression in review
Review explores potential kidney cancer treatment target and challenges
A review article summarizes literature on the PI3K-AKT-mTOR signaling pathway in renal cell carcinoma (RCC). The pathway is often abnormally…
Kidney cancer tumors often overactivate a cell pathway that drives growth and spreading, prompting doctors to explore blocking it with new d…